Several studies have demonstrated that immunotherapy combined with anti-HER2 treatment and chemotherapy in a neoadjuvant setting can achieve an acceptable pCR rate (22, 23), while single-agent immunotherapy showed limited efficacy compared with endocrine treatment and targeted therapy, which are now the mainstay treatment for this group of breast cancer patients (24). This evidence concerns the gene ERBB2 and breast cancer.